Paola Rivera
University of Genoa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paola Rivera.
Journal of Experimental Medicine | 2003
Cristina Bottino; Roberta Castriconi; Daniela Pende; Paola Rivera; Marina Nanni; Barbara Carnemolla; Claudia Cantoni; Jessica Grassi; Stefania Marcenaro; Nicolas Reymond; Massimo Vitale; Lorenzo Moretta; Marc Lopez; Alessandro Moretta
Human natural killer (NK) cells express a series of activating receptors and coreceptors that are involved in recognition and killing of target cells. In this study, in an attempt to identify the cellular ligands for such triggering surface molecules, mice were immunized with NK-susceptible target cells. On the basis of a functional screening, four mAbs were selected that induced a partial down-regulation of the NK-mediated cytotoxicity against the immunizing target cells. As revealed by biochemical analysis, three of such mAbs recognized molecules of ∼70 kD. The other mAb reacted with two distinct molecules of ∼65 and 60 kD, respectively. Protein purification followed by tryptic digestion and mass spectra analysis, allowed the identification of the 70 kD and the 65/60 kD molecules as PVR (CD155) and Nectin-2 δ/α (CD112), respectively. PVR-Fc and Nectin-2-Fc soluble hybrid molecules brightly stained COS-7 cells transfected with the DNAM-1 (CD226) construct, thus providing direct evidence that both PVR and Nectin-2 represent specific ligands for the DNAM-1 triggering receptor. Finally, the surface expression of PVR or Nectin-2 in cell transfectants resulted in DNAM-1–dependent enhancement of NK-mediated lysis of these target cells. This lysis was inhibited or even virtually abrogated upon mAb-mediated masking of DNAM-1 (on NK cells) or PVR or Nectin-2 ligands (on cell transfectants).
European Journal of Immunology | 2001
Daniela Pende; Claudia Cantoni; Paola Rivera; Massimo Vitale; Roberta Castriconi; Stefania Marcenaro; Marina Nanni; Roberto Biassoni; Cristina Bottino; Alessandro Moretta; Lorenzo Moretta
NKG2D is a recently described activating receptor expressed by both NK cells and CTL. In this study we investigated the role of NKG2D in the natural cytolysis mediated by NK cell clones. The role of NKG2D varied depending on the type of target cells analyzed. Lysis of various tumors appeared to be exclusively natural cytotoxicity receptors (NCR) dependent. In contrast, killing of anothergroup of target cells, including not only the epithelial cell lines HELA and IGROV‐1, but also the FO‐1 melanoma, the JA3 leukemia, the Daudi Burkitt lymphoma and even normal PHA‐induced lymphoblasts, involved both NCR and NKG2D. Notably, NK cell clones expressing low surface densities of NCR (NCRdull) could lyse these tumors in an exclusively NKG2D‐dependent fashion. Remarkably, notall of these targets expressed MICA/B, thus implying the existence of additional ligands recognized by NKG2D, possibly represented by GPI‐linked molecules. Finally, we show that the engagement of different HLA class I‐specific inhibitory receptors by either specific antibodies or the appropriate HLA class I ligand led to inhibition of NKG2D‐mediated NK cell triggering.
European Journal of Immunology | 2001
Grazia Maria Spaggiari; Roberta Carosio; Daniela Pende; Stefania Marcenaro; Paola Rivera; Maria Raffaella Zocchi; Lorenzo Moretta; Alessandro Poggi
Interleukin‐2 (IL‐2)‐activated polyclonal or clonal NK cells lysed autologous antigen presenting cells (APC) through the engagement of the natural cytotoxicity receptors (NCR) NKp30 and NKp46. NK cell‐mediated cytolysis of APC correlated with the surface density of these NCR. Indeed, NK cell clones bearing low amounts of NKp30 and NKp46 did not lyse autologous APC, whereas NK cell clones with bright expression of these NCR efficiently killed autologous APC. Upon masking of NKp30 or NKp46 by specific monoclonal antibodies a strong reduction (by 50%) of APC lysis could be detected and the complete inhibition was achieved by the simultaneous masking of these NCR. Interestingly, NK cell‐mediated APC lysis was impaired by the phosphatidylinositol 3‐kinase (PI‐3 K) inhibitors LY294002 or wortmannin. Similarly, these drugs strongly reduced NK cell activation triggered by NKp30 or NKp46 in a re‐directed killing assay as well as the activation of Akt/PKB, substrate of PI‐3 K, induced by the engagement of these receptors. Altogether, these findings strongly suggest that NCR are responsible for the killing of autologous APC through the activation of PI‐3 K.
Cancer Research | 2004
Francesco Lozupone; Daniela Pende; Vito L. Burgio; Chiara Castelli; Massimo Spada; Massimo Venditti; Francesca Luciani; Luana Lugini; Cristina Federici; Carlo Ramoni; Licia Rivoltini; Giorgio Parmiani; Filippo Belardelli; Paola Rivera; Stefania Marcenaro; Lorenzo Moretta; Stefano Fais
Natural killer (NK) cells were first identified for their ability to kill tumor cells of different origin in vitro. Similarly, γδ T lymphocytes display strong cytotoxic activity against various tumor cell lines. However, the ability of both the NK and γδ cells to mediate natural immune response against human malignant tumors in vivo is still poorly defined. Severe combined immunodeficient (SCID) mice have been successfully engrafted with human tumors. In this study, the antitumor effect of local as well as of systemic treatments based on NK cells or Vδ1 or Vδ2 γ/δ T lymphocytes against autologous melanoma cells was investigated in vivo. The results show that all three of the populations were effective in preventing growth of autologous human melanomas when both tumor and lymphoid cells were s.c. inoculated at the same site. However, when lymphoid cells were infused i.v., only NK cells and Vδ1 γ/δ T lymphocytes could either prevent or inhibit the s.c. growth of autologous melanoma. Accordingly, both NK cells and Vδ1 γδ T lymphocytes could be detected at the s.c. tumor site. In contrast, Vδ2 γδ T lymphocytes were only detectable in the spleen of the SCID mice. Moreover, NK cells maintained their inhibitory effect on tumor growth even after discontinuation of the treatment. Indeed they were present at the tumor site for a longer period. These data support the possibility to exploit NK cells and Vδ1 γδ T lymphocytes in tumor immunotherapy. Moreover, our study emphasizes the usefulness of human tumor/SCID mouse models for preclinical evaluation of immunotherapy protocols against human tumors.
Cancer Research | 2002
Daniela Pende; Paola Rivera; Stefania Marcenaro; Chien-Chung Chang; Roberto Biassoni; Romana Conte; Marek Kubin; David Cosman; Soldano Ferrone; Lorenzo Moretta; Alessandro Moretta
Blood | 2005
Daniela Pende; Grazia Maria Spaggiari; Stefania Marcenaro; Stefania Martini; Paola Rivera; Andrea Capobianco; Michela Falco; Edoardo Lanino; Ivana Pierri; Renato Zambello; Andrea Bacigalupo; Maria Cristina Mingari; Alessandro Moretta; Lorenzo Moretta
Blood | 2006
Daniela Pende; Roberta Castriconi; Paola Romagnani; Grazia Maria Spaggiari; Stefania Marcenaro; Alessandra Dondero; Elena Lazzeri; Laura Lasagni; Stefania Martini; Paola Rivera; Andrea Capobianco; Lorenzo Moretta; Alessandro Moretta; Cristina Bottino
Molecular Immunology | 2005
Daniela Pende; Cristina Bottino; Roberta Castriconi; Claudia Cantoni; Stefania Marcenaro; Paola Rivera; Grazia Maria Spaggiari; Alessandra Dondero; Barbara Carnemolla; Nicolas Reymond; Maria Cristina Mingari; Marc Lopez; Lorenzo Moretta; Alessandro Moretta
International Immunology | 2004
Massimo Vitale; Simona Carlomagno; Michela Falco; Daniela Pende; Elisa Romeo; Paola Rivera; Mariella Della Chiesa; Domenico Mavilio; Alessandro Moretta
Archive | 2013
Maria Cristina Mingari; Alessandro Moretta; Lorenzo Moretta; Michela Falco; Edoardo Lanino; Ivana Pierri; Renato Zambello; Andrea Bacigalupo; Daniela Pende; Grazia Maria Spaggiari; Stefania Marcenaro; Stefania Martini; Paola Rivera